Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Attovia Therapeutics, Inc. (ATTO)

Attovia Therapeutics Q3 net loss widens to $22.3 million; cash $395.9 million

Negative Impact 3 of 5 earnings

Attovia Therapeutics reported third quarter 2026 results on November 9, 2026, with a net loss of $22.3 million, up from $13.8 million a year earlier, and no collaboration revenue compared with $0.4 million in the prior-year quarter. The company also disclosed 12-week Phase 1b data for ATTO-1310 in chronic pruritus and high-itch atopic dermatitis, and said it expects two Phase 2 trials to start in the first half of 2027. Cash, cash equivalents, and marketable securities of $395.9 million are expected to fund operations into 2030.

Key points

  • Net loss was $22.3 million for Q3 2026, compared with $13.8 million for Q3 2025.
  • Collaboration revenue was zero in Q3 2026, compared with $0.4 million in Q3 2025.
  • Research and development expenses rose to $20.3 million from $12.3 million, driven by ATTO-1310 and preclinical programs.
  • At Week 12 in chronic pruritus patients, 82% of ATTO-1310-treated patients achieved PP-NRS4 vs. 22% with placebo; Phase 2 ATTUNE trials are on track to start in the first half of 2027.

The filing

CompanyAttovia Therapeutics, Inc. (ATTO)
Form8-K, current report
Filed with the SECNov 9, 2026, 4:10 PM ET
Accession number0001193125-26-453592

Items reported: 2.02 Results of Operations8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 6:16 PM ET, from this filing only.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.